OUR MISSION: TO SERVE PATIENTS AMGEN harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We discover, develop, manufacture and deliver innovative medicines to help millions of patients. Our investment in R&D has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
AMVS - Austrian Medicines Verification System GmbH is implementing the EU False Medicines Directive in Austria. AMVS supports all stakeholders in the pharmaceutical supply chain. The national medicines verification system protects the legal supply chain against intrusion of falsified medicines.
ANTISEPTICA AUSTRIA was founded in 2000 and is a subsidiary of ANTISEPTICA Germany. We are professionals in the field of hygiene for safe and reliable use and offer our customers high quality, tested and certified disinfectants as well as hygiene products.
APEIRON Biologics AG at a glance: APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies. APEIRON Biologics´ projects and technologies are based on a strong patent portfolio and partnerships with leading pharmaceutical companies and academic institutions.
APEPTICO Forschung und Entwicklung GmbH is a privately-held development stage biotechnology company in Vienna, Austria, developing peptide-based products targeting life-threatening pulmonary diseases.
Aposcience AG is unique in having developed a secretome-based regenerative therapy. The secretome is produced under GMP-conditions and was approved by the Austrian regulatory agency for a clinical phase II trial. Our product platform Aposec consists of two products: APO-1 - Aposec for internal diseases (acute myocardial infarction, spinal cord injury and stroke) APO-2 - Aposec for topical application (hard-healing wounds, diabetic ulcers)
ARAX Capital Partners is one of the leading venture capitalists in Austria. We have been financing emerging Austrian high-tech and biotech companies in the high-tech and biotech sectors since 2007. One of our driving success factors are the complementary skills of our multidisciplinary team. We are convinced that besides quality, the diversity of experience backgrounds is essential. Our experienced management team has industry expertise and is characterized by first-class industry know-how.
The ASKIN